GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company developing drugs to treat Alzheimer's disease. Its stock price is highly volatile, driven by news of clinical trials in one of the most complex and risky areas of pharmaceuticals.
Share prices of companies in the market segment - Neuro
Acumen Pharmaceuticals is a clinical-stage biotech company developing a targeted therapy against beta-amyloid oligomers for the treatment of Alzheimer's disease. We have classified it in the "Neuro" segment. The chart below shows the overall dynamics in this complex and risky sector, which is seeking a breakthrough in the treatment of neurodegenerative diseases.
Broad Market Index - GURU.Markets
Acumen Pharmaceuticals is a biopharmaceutical company developing targeted drugs for the treatment of Alzheimer's disease. Its focus on this complex problem makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Acumen compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ABOS - Daily change in the company's share price Acumen Pharmaceuticals
For Acumen Pharmaceuticals, which is developing a drug for Alzheimer's disease, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Neuro
For Acumen Pharmaceuticals, which is developing a drug for Alzheimer's disease, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment formulas.
Daily change in the price of a broad market stock, index - GURU.Markets
Acumen Pharmaceuticals is a biotech company developing a drug to treat Alzheimer's disease. Its shares are known for their high volatility, driven by expectations and clinical trial results. This is a prime example of how a single story can create powerful waves in the market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Acumen Pharmaceuticals
For Acumen Pharmaceuticals, the year-to-date performance is a story about developing a new approach to treating Alzheimer's disease. Its 12-month market cap depends entirely on clinical trial data for its antibody targeting toxic beta-amyloid oligomers. Success could be a breakthrough, but the risks in this field are extremely high.
Annual dynamics of market capitalization of the market segment - Neuro
Acumen Pharmaceuticals, Inc. is a clinical-stage biotech company developing drugs for the treatment of Alzheimer's disease. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the significant risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Acumen is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its Alzheimer's drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Acumen Pharmaceuticals
Acumen Pharmaceuticals is a clinical-stage biotech company targeting Alzheimer's disease. Its monthly performance is entirely dependent on news about its clinical trials. The results of its lead antibody trials are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Neuro
Acumen Pharmaceuticals is a clinical-stage biotech company developing drugs to treat Alzheimer's disease. Its value depends almost entirely on the results of clinical trials in one of the most complex areas of medicine. The neuroscience segment of the pharmaceutical market reflects the high hopes and frequent setbacks typical of this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Acumen Pharmaceuticals is a biotech company developing a cure for Alzheimer's disease. This is one of the most complex and capital-intensive areas of medicine. The company's shares are driven solely by news of clinical trials. Their performance is completely disconnected from market cycles and reflects only investor hopes for a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Acumen Pharmaceuticals
Acumen Pharmaceuticals, a clinical-stage biotech focused on Alzheimer's disease, is experiencing extreme volatility. Weekly stock performance is driven by news about clinical trials and efficacy data for its drug candidates.
Weekly dynamics of market capitalization of the market segment - Neuro
Acumen Pharmaceuticals is developing a therapy targeting beta-amyloid oligomers for the treatment of Alzheimer's disease. This chart compares its volatile, news-driven performance with overall trends in the neuroscience sector and assesses investor confidence in its scientific approach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Acumen Pharmaceuticals is developing a drug for Alzheimer's disease. Its shares are extremely volatile and move based on research news. The chart clearly shows that ABOS's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
ABOS - Market capitalization of the company Acumen Pharmaceuticals
The Acumen Pharmaceuticals chart is a financial map of the fight against Alzheimer's disease. This biotech company's market cap reflects the hopes for its antibody, which targets toxic forms of amyloid. Its performance is a barometer of progress in clinical trials in one of the most complex and in-demand areas of medicine.
ABOS - Share of the company's market capitalization Acumen Pharmaceuticals within the market segment - Neuro
Acumen Pharmaceuticals' stake in the neuroscience sector is a bet on a new approach to treating Alzheimer's disease. The company focuses on toxic beta-amyloid oligomers. Its market share reflects the potential of its lead candidate to become a breakthrough drug in this highly complex area of medicine.
Market capitalization of the market segment - Neuro
Acumen Pharmaceuticals is a biotech company focused on fighting Alzheimer's disease. The chart below shows the overall market capitalization of this complex sector. Its extremely volatile dynamics reflect the enormous hopes and risks involved in finding a cure.
Market capitalization of all companies included in a broad market index - GURU.Markets
Acumen Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of Alzheimer's disease that target beta-amyloid oligomers. Its market capitalization is a bet on this scientific approach. The chart below shows the weightings of companies pursuing a cure for this disease.
Book value capitalization of the company, segment and market as a whole
ABOS - Book value capitalization of the company Acumen Pharmaceuticals
For Acumen Pharmaceuticals, a biopharmaceutical company, book value represents its R&D capital. The chart below shows its financial resources for developing Alzheimer's drugs. This level is an indicator of its ability to finance lengthy and expensive clinical trials.
ABOS - Share of the company's book capitalization Acumen Pharmaceuticals within the market segment - Neuro
Acumen Pharmaceuticals is a clinical-stage biotech company developing a drug for Alzheimer's disease. Its value lies in the potential of its drug. The tangible asset share chart will be minimal, emphasizing the focus on intangible assets: patents and research data.
Market segment balance sheet capitalization - Neuro
Acumen Pharmaceuticals is a clinical-stage biotech company. Its value is created in the labs where it's developing a drug for Alzheimer's disease. This is a "light" model. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Acumen Pharmaceuticals' balance sheet represents capital focused on developing antibodies targeting beta-amyloid oligomers for the treatment of Alzheimer's disease. The book value chart shows the amount of resources devoted to this specific and potentially key target in the fight against the disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company developing antibodies to treat Alzheimer's disease. Its market capitalization is a pure bet on the success of its lead candidate. The chart reflects the extreme sensitivity to any news about clinical trials in this highly complex area of medicine.
Market to book capitalization ratio in a market segment - Neuro
Acumen Pharmaceuticals is a biotech company developing a treatment for Alzheimer's disease. Its value is entirely dependent on the success of clinical trials. The chart demonstrates the enormous premium investors are paying for the hope of a breakthrough in treating this complex disease.
Market to book capitalization ratio for the market as a whole
Acumen Pharmaceuticals is a biotech company developing drugs to treat Alzheimer's disease. The chart illustrates the enormous hopes and risks. The company's market capitalization is a pure bet on the success of its clinical trials. It has no correlation to its tangible assets and is extremely volatile.
Debts of the company, segment and market as a whole
ABOS - Company debts Acumen Pharmaceuticals
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating Alzheimer's disease. For such a company, debt is a way to finance the lengthy and extremely expensive clinical trials of its targeted drug, as reflected in this chart.
Market segment debts - Neuro
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in Alzheimer's disease. They are developing antibodies against toxic beta-amyloid oligomers. The chart illustrates the financial norms for the biotech sector, against which Acumen is raising significant capital to finance its lengthy and very expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company focused on developing therapies against the toxic proteins that cause Alzheimer's disease. This is one of the most complex and risky areas in medicine. This chart shows how much the company relies on debt to fund its research, which is a direct indicator of its financial risk.
Market segment debt to market segment book capitalization - Neuro
Alzheimer's drug development, Acumen's focus, is one of the most complex and risky areas in pharmaceuticals. This chart shows how the biotech sector finances its most ambitious projects. It allows one to assess how dependent Acumen Pharmaceuticals' financial model is on clinical trial success and external capital compared to the industry.
Debt to book value of all companies in the market
Acumen Pharmaceuticals is developing a therapy for Alzheimer's disease that targets amyloid plaques. This is one of the most complex challenges in modern medicine, requiring enormous capital. The chart shows how their debt load for R&D funding compares to the overall biopharma market.
P/E of the company, segment and market as a whole
P/E - Acumen Pharmaceuticals
This chart shows the valuation of Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing drugs to treat Alzheimer's disease. Its value is determined not by current earnings, but by investors' faith in its scientific approach. The chart reflects hopes for a breakthrough in this complex area of medicine.
P/E of the market segment - Neuro
This indicator represents the average valuation for the biotech sector in which Acumen Pharmaceuticals operates. It reflects the overall level of hope and risk in the Alzheimer's disease treatment field. The chart serves as a barometer of investor sentiment for the entire development segment in this complex field.
P/E of the market as a whole
Acumen Pharmaceuticals is a biotech company developing drugs for the treatment of Alzheimer's disease that target beta-amyloid oligomers. This is a highly specific scientific approach. This chart shows the sentiment in biotech. It helps understand how the market views this specific scientific approach in one of the most complex and risky areas of pharmaceuticals, one fraught with high-profile failures.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company developing treatments for Alzheimer's disease by targeting soluble beta-amyloid oligomers. Its future hinges on the success of clinical trials. This chart reflects the high, yet speculative, investor expectations for its unique scientific approach to one of the most challenging problems in medicine.
%20P%2FE%20Acumen%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Acumen-Pharmaceuticals&v=1772601872560 "Chart of the company's future (projected) P/E Acumen Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
Acumen Pharmaceuticals is a biotech company developing drugs for the treatment of Alzheimer's disease that target beta-amyloid oligomers. This is a unique approach in a very complex field. The chart reflects expectations for the biotech sector, providing context for assessing how the market views Acumen's scientific hypothesis and risks.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772601872587 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Acumen Pharmaceuticals is a clinical-stage biotechnology company developing a therapy targeting soluble beta-amyloid oligomers for the treatment of Alzheimer's disease. This graph of overall expectations demonstrates the investor appetite for risky research projects. Market optimism and faith in science are essential for attracting massive funding to fight this devastating disease.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772601872613 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Acumen Pharmaceuticals
Acumen Pharmaceuticals is a clinical-stage biotech company focused on developing anti-amyloid beta oligomer therapy for the treatment of Alzheimer's disease. This chart shows the cost of treating this complex disease. Future profitability depends entirely on the success of clinical trials and approval of its targeted approach.
Profit of companies in the market segment - Neuro
Eastern International Ltd. is likely a logistics company. Its profitability depends on shipping volumes and freight rates. This chart reflects the cyclicality and competition in the transportation sector, where economic cycles, fuel prices, and geopolitics directly impact the financial performance of all participants.
Overall market profit
Acumen Pharmaceuticals is a biotechnology company developing targeted therapy against beta-amyloid oligomers for the treatment of Alzheimer's disease. The company is at the forefront of science in one of the most complex areas of medicine. Its success depends solely on the results of clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company developing drugs targeting beta-amyloid oligomers for the treatment of Alzheimer's disease. Its revenue outlook is long-term and depends on the success of clinical trials. This chart reflects analyst expectations for its unique approach to combating one of the most complex diseases.
%20profit%20of%20the%20company%20Acumen%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Acumen-Pharmaceuticals&v=1772601872832 "Graph of future (projected) profit of the company Acumen Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
Acumen Pharmaceuticals is a clinical-stage biotechnology company developing antibodies targeting soluble beta-amyloid oligomers for the treatment of Alzheimer's disease. This chart shows profitability projections for the neuroscience sector. It reflects the enormous hopes and scientific challenges associated with finding an effective treatment for this devastating disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772601872855 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Acumen Pharmaceuticals is a biotech company specializing in developing treatments for Alzheimer's disease. Its success depends entirely on the results of clinical trials. However, the overall corporate earnings forecast presented in this chart forms an investment backdrop and influences investors' willingness to fund long-term, high-risk projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772601872906 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company developing antibodies targeting beta-amyloid oligomers for the treatment of Alzheimer's disease. Currently in the clinical stage, it has no revenue. The chart reflects investor assessments of its scientific approach, which may prove more effective than competitors', but is associated with high risks.
P/S market segment - Neuro
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a targeted therapy for Alzheimer's disease targeting soluble beta-amyloid oligomers. This chart shows the average valuation in the sector, allowing one to assess the market's perception of the revenue potential of Acumen's scientific approach.
P/S of the market as a whole
Acumen Pharmaceuticals is a biotech company developing antibodies targeting soluble beta-amyloid oligomers for the treatment of Alzheimer's disease. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on a scientific breakthrough in treating one of the most complex diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biopharmaceutical company focused on developing Alzheimer's disease treatments targeting soluble beta-amyloid oligomers. This chart reflects investor confidence in the future success of this approach. The valuation is based on expectations for clinical trials that could lead to a breakthrough drug.
%20P%2FS%20Acumen%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Acumen-Pharmaceuticals&v=1772601873054 "The graph of the company's future (projected) P/S Acumen Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
Acumen Pharmaceuticals is a biotech company developing drugs targeting beta-amyloid oligomers for the treatment of Alzheimer's disease. The chart shows the premium investors are willing to pay for Acumen's future sales, reflecting the high expectations for its potentially breakthrough approach to combating this disease.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772601873070 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
This graph reflects the enormous hopes associated with finding a cure for Alzheimer's disease. Acumen Pharmaceuticals is developing antibodies that target beta-amyloid oligomers, which are believed to be one of the causes of the disease. Their scientific approach is part of a global effort to combat the disease, and any success in this area will have a profound impact on society and the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772601873084 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Acumen Pharmaceuticals
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies against toxic beta-amyloid oligomers for the treatment of Alzheimer's disease. Currently, the company has no commercial sales revenue. Its financials reflect investments in its cutting-edge research.
Sales of companies in the market segment - Neuro
Acumen Pharmaceuticals is a biotech company developing antibodies targeting soluble beta-amyloid oligomers for the treatment of Alzheimer's disease. This chart shows the company's total revenue in the neuroscience pharmaceutical segment. It illustrates the company's intensive research and significant investment in the fight against Alzheimer's, where Acumen offers a unique approach.
Overall market sales
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing anti-amyloid beta oligomer therapy for the treatment of Alzheimer's disease. Its valuation is entirely dependent on the results of clinical trials. This overall economic climate influences investor willingness to fund high-risk but potentially breakthrough research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company developing a therapy targeting beta-amyloid oligomers for the treatment of Alzheimer's disease. The future depends on the success of clinical trials. The chart shows analysts' speculative forecasts, which are betting on a new approach to combating this neurodegenerative disease.
%20sales%20of%20the%20company%20Acumen%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Acumen-Pharmaceuticals&v=1772601873249 "Schedule of future (projected) sales of the company Acumen Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
Acumen Pharmaceuticals is a biotech company developing antibodies targeting soluble beta-amyloid oligomers for the treatment of Alzheimer's disease. Success depends on clinical data. This chart reflects forecasts for the entire neurological pharmaceutical segment, showing analysts' overall expectations for the Alzheimer's drug market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772601873296 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapy against toxic beta-amyloid oligomers for the treatment of Alzheimer's disease. Its future depends entirely on the success of clinical trials. This overall economic activity schedule impacts the availability of capital for funding long-term and high-risk biotech projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772601873324 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company developing targeted anti-amyloid beta therapy for the treatment of Alzheimer's disease. This indicator reflects the financial aspect of its scientific mission, demonstrating the level of investment in clinical trials required to bring a new generation of drugs to market.
Market segment marginality - Neuro
Acumen Pharmaceuticals is a biotech company developing drugs targeting beta-amyloid oligomers for the treatment of Alzheimer's disease. Profitability is a long-term goal. This metric reflects its operational structure and the level of investment in its unique scientific approach compared to other neurobiotech companies.
Market marginality as a whole
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing antibodies targeting beta-amyloid oligomers for the treatment of Alzheimer's disease. Their success depends entirely on the results of clinical trials. This overall profitability curve doesn't affect their research activities, but it is important for attracting investment in the risky biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech company focused on developing therapies against toxic beta-amyloid oligomers, a key target in Alzheimer's disease. Currently in the clinical stage, it has a compact team. This chart shows the dynamics of the scientific team leading research in one of the most complex areas of medicine.
Share of the company's employees Acumen Pharmaceuticals within the market segment - Neuro
Acumen Pharmaceuticals is a biopharmaceutical company developing anti-beta-amyloid oligomer therapy for the treatment of Alzheimer's disease. This chart shows the concentration of leading neuroscientists. This proportion reflects its focused scientific approach to one of the most challenging targets in medicine.
Number of employees in the market segment - Neuro
Acumen Pharmaceuticals, Inc. is a biotechnology company developing beta-amyloid-targeted therapies for the treatment of Alzheimer's disease. This chart shows overall employment in the neuroscience sector. It illustrates the company's focused scientific approach as it attempts to address one of the suspected key causes of the disease.
Number of employees in the market as a whole
Acumen Pharmaceuticals is a biotech company focused on developing therapies against toxic beta-amyloid oligomers, which are believed to be the key cause of Alzheimer's disease. This employment chart reflects the contribution of research-intensive companies that, despite their small staffs, are solving global health problems by attracting the best scientific minds.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals is a biopharmaceutical company developing a treatment for Alzheimer's disease. This chart is a prime example of biotech. The astronomically high market capitalization per employee means the market is valuing the potential of a blockbuster drug, not the operational performance of a small research team. The price is based on the hopes of a breakthrough.
%20of%20the%20company%20Acumen%20Pharmaceuticals%20(ABOS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Acumen-Pharmaceuticals-ABOS&v=1772601873585 "Chart of market capitalization per employee (in thousands of dollars) of the company Acumen Pharmaceuticals (ABOS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Acumen Pharmaceuticals is a biotech company focused on developing a treatment for Alzheimer's disease. Their entire value is tied to the potential of a single key drug. This metric demonstrates the enormous value the market places on their research. This high metric reflects investor hopes for a breakthrough in one of the most complex areas of medicine.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772601873632 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on Alzheimer's disease. Its value depends almost entirely on the success of its lead candidate. This metric demonstrates the extreme dependence of valuation on scientific data in biotech, where a single success can create a multibillion-dollar company.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772601873687 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals (ABOS) is a clinical-stage biotech R&D company focused on treating Alzheimer's disease. It's pure science. This metric measures their capital burn rate—the net loss (expenses on clinical research) per employee.
%20Chart%20Acumen%20Pharmaceuticals%20(ABOS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Acumen-Pharmaceuticals-ABOS&v=1772601873732 "Company Profit Per Employee (in thousands of dollars) Chart Acumen Pharmaceuticals (ABOS)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Acumen Pharmaceuticals is a clinical-stage biotech focused on treating Alzheimer's disease. Like other R&D firms, this timeline is a goal for the future. Currently, all value lies in the intellectual potential of their research team. A successful drug will allow them to generate profits above the industry average.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772601873820 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Acumen Pharmaceuticals (ABOS) is a clinical-stage biotech company specializing in Alzheimer's disease, specifically toxic beta-amyloid oligomers. This is R&D. This chart shows the typical biotech picture: negative profit per employee, as all resources are invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772601873903 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Acumen Pharmaceuticals (ABOS)
For Acumen Pharmaceuticals, a company developing a treatment for Alzheimer's disease, this graph reflects the clinical trial stage. Future revenue growth per employee depends entirely on the success of its drug candidate in treating this complex disease.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Acumen-Pharmaceuticals-ABOS&v=1772601873956 "Sales chart per company employee Acumen Pharmaceuticals (ABOS)")
Sales per employee in the market segment - Neuro
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating Alzheimer's disease by targeting beta-amyloid oligomers. This is R&D. This metric reflects the average revenue per employee in the segment. It demonstrates how productive their research team is in this highly complex field compared to other biotech companies.
Sales per employee for the market as a whole
Acumen Pharmaceuticals (ABOS) is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease. Currently, its staff consists entirely of researchers. This metric is critical for ABOS: it's at zero. Future growth will signal the success of their R&D and the receipt of partner fees.
Short shares by company, segment and market as a whole
Shares shorted by company Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals is a clinical-stage biotech company also working in the highly competitive field of Alzheimer's disease. It's betting on a specific target (amyloid oligomers). This chart shows how many investors are betting that its drug will fail in trials, like dozens of other Alzheimer's drugs before it.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Acumen-Pharmaceuticals-ABOS&v=1772601874062 "Short Shares Chart for the Company Acumen Pharmaceuticals (ABOS)")
Shares shorted by market segment - Neuro
Acumen Pharmaceuticals (ABOS) is a biopharmaceutical company focused on treating Alzheimer's disease by targeting toxic amyloid-beta oligomers. This chart shows the cumulative short position across the entire Alzheimer's drug development sector. It reflects the market's immense skepticism about this highly complex area of medicine, which has seen decades of failure.
Shares shorted by the overall market
Acumen (ABOS) is a clinical-stage biotech company working on Alzheimer's disease. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Acumen Pharmaceuticals (ABOS)
This oscillator is a barometer of hope for Acumen Pharmaceuticals in the fight against Alzheimer's disease. The company is targeting beta-amyloid oligomers, a novel approach. Any positive clinical trial data, even early ones, triggers euphoria and "overheating" (above 70). A study failure or safety concerns (such as ARIA brain edema) lead to panic (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Acumen-Pharmaceuticals-ABOS&v=1772601874229 "RSI 14 indicator chart for the company's stock Acumen Pharmaceuticals (ABOS)")
RSI 14 Market Segment - Neuro
Acumen (ABOS) is a biotech company and an Alzheimer's hunter. Their specialty is antibodies targeting beta-amyloid oligomers (the most toxic form). The Neuro (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether ABOS's rise is due to Alzheimer's hype, or is the entire biotech sector overheated?
RSI 14 for the overall market
Acumen Pharma (ABOS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ABOS (Acumen Pharmaceuticals)
Acumen Pharmaceuticals is a biotech company focused on treating Alzheimer's disease. Its approach is developing antibodies that target toxic beta-amyloid oligomers. This chart shows the speculative average price target from analysts, which is almost entirely dependent on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ABOS-Acumen-Pharmaceuticals&v=1772601874355 "A chart showing analyst consensus forecasts for the expected stock price. ABOS (Acumen Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ABOS (Acumen Pharmaceuticals)
Acumen (ABOS) is a biotech developing antibodies to treat Alzheimer's disease. This chart is a barometer of their R&D. It measures the vast gap between the speculative price and the consensus target, reflecting the enormous (but risky) potential analysts see in their pipeline for this complex disease.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ABOS-Acumen-Pharmaceuticals&v=1772601874376 "A chart showing the difference between the consensus forecast and the actual stock price. ABOS (Acumen Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
Acumen Pharmaceuticals is a biotech company focused on Alzheimer's disease. It develops antibodies that target toxic beta-amyloid oligomers. This chart shows general expectations for the neuroscience sector. It reflects whether experts believe a breakthrough in Alzheimer's treatment is possible or whether they consider the sector too risky.
Analysts' consensus forecast for the overall market share price
Acumen Pharmaceuticals is a biotech company developing Alzheimer's disease treatments targeting toxic beta-amyloid oligomers. This chart shows the company's overall risk appetite. For Acumen, which operates in the most complex area of medicine, overall market optimism is critical to funding long-term, expensive trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Acumen Pharmaceuticals
Acumen is a clinical-stage biotech company attacking the holy grail: Alzheimer's disease. Their focus isn't on plaques, but on toxic beta-amyloid oligomers, which are considered an early driver of the disease. This chart is a pure indicator of their faith in R&D. It doesn't reflect revenue, but rather a speculative assessment of their scientific approach and clinical trial data.
AKIMA Market Segment Index - Neuro
Acumen Pharmaceuticals (ABOS) is a clinical-stage biotech company focused on treating Alzheimer's disease by targeting beta-amyloid oligomers. The chart shows the segment average. It allows investors to compare Acumen's high risk with the overall neuroscience research landscape, where setbacks are as common as the promise of breakthroughs.
The AKIM Index for the overall market
Acumen Pharmaceuticals is a biotech company developing antibodies targeting toxic amyloid-beta oligomers (caused by Alzheimer's disease). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story in the competitive field of neuroscience compares to overall economic trends and competitors' successes.
